A Swedish pharmaceutical company, AlzeCure Pharma, has shared exciting new results from a clinical trial of its pain-relief gel, ACD440, at an international pain conference. The study focused on people with chronic nerve pain, and the results suggest the gel could reduce pain by about 50%—a meaningful improvement for patients. Unlike many pain medications that work throughout the body, this gel is designed to work only where it’s applied, reducing the risk of side effects. The drug is based on groundbreaking science that earned a Nobel Prize. The company has also received special recognition from the FDA for using this gel to treat a rare, painful condition called erythromelalgia. Experts believe these results could make the treatment attractive to other drug companies and investors.